Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncological strategy for unilobar hepatocellular carcinoma regardless of the tumor burden. Issue 8 (August 2016)
- Record Type:
- Journal Article
- Title:
- Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncological strategy for unilobar hepatocellular carcinoma regardless of the tumor burden. Issue 8 (August 2016)
- Main Title:
- Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncological strategy for unilobar hepatocellular carcinoma regardless of the tumor burden
- Authors:
- Ronot, Maxime
Cauchy, François
Gregoli, Bettina
Breguet, Romain
Allaham, Wassim
Paradis, Valérie
Soubrane, Olivier
Vilgrain, Valérie - Abstract:
- Abstract: Objective: To investigate the long-term oncological outcome of patients with resectable hepatocellular carcinoma (HCC) undergoing sequential transarterial chemoembolization (TACE) and portal vein embolization (PVE). Methods: Analysis of all Child A HCC patients who underwent TACE-PVE before major liver resection from 2006 to 2012 was performed according to whether or not they underwent surgical resection as planned. Results: 54 patients (50 men, 93% median 69-years (range 44–87)) were included. Thirty-nine (72%) patients underwent resection, including 19/25, 16/23, and 4/6 of patients with BCLC A, B, and C (p = 0.839). Twenty-two (56%) had tumor recurrence (median delay 10 months) including 9/19, 11/16, and 2/4 of the patients with BCLC A, B, and C (p = 0.430). Survival was significantly better in resected patients as compared to those who were not resected (median overall survival (OS): 44 vs. 18 months; p < 0.001). Recurrence was associated with a poorer prognosis as compared to patients without recurrence (median OS 43 months vs. not reached; p < 0.001). BCLC stage did not influence survival (p = 0.13). Conclusion: In patients with large unilobar HCC, TACE-PVE leads to resection in most patients, with a good oncological outcome regardless of the tumor burden. When this strategy fails, patients can be managed with TACE despite prior PVE.
- Is Part Of:
- HPB. Volume 18:Issue 8(2016)
- Journal:
- HPB
- Issue:
- Volume 18:Issue 8(2016)
- Issue Display:
- Volume 18, Issue 8 (2016)
- Year:
- 2016
- Volume:
- 18
- Issue:
- 8
- Issue Sort Value:
- 2016-0018-0008-0000
- Page Start:
- 684
- Page End:
- 690
- Publication Date:
- 2016-08
- Subjects:
- Liver -- Diseases -- Periodicals
Biliary tract -- Diseases -- Periodicals
Pancreas -- Diseases -- Periodicals
616.362005 - Journal URLs:
- https://www.journals.elsevier.com/hpb/ ↗
http://www.hpbonline.org/current ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1477-2574 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1016/j.hpb.2016.05.012 ↗
- Languages:
- English
- ISSNs:
- 1365-182X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4335.262340
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 5680.xml